These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 8673718)

  • 1. Mangafodipir trisodium injection (Mn-DPDP). A contrast agent for abdominal MR imaging.
    Rofsky NM; Earls JP
    Magn Reson Imaging Clin N Am; 1996 Feb; 4(1):73-85. PubMed ID: 8673718
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Manganese (II) N,N'-dipyridoxylethylenediamine-N,N'-diacetate 5,5'-bis(phosphate): clinical experience with a new contrast agent.
    Rofsky NM; Weinreb JC
    Magn Reson Q; 1992 Sep; 8(3):156-68. PubMed ID: 1390058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The clinical value of Mn-DPDP: a new paramagnetic hepatobiliary contrast medium for magnetic resonance tomography of the liver].
    Vogl TJ; Hamm B; Schnell B; Eibl-Eibesfeldt B; Steiner S; Lissner J
    Rofo; 1991 Dec; 155(6):568-74. PubMed ID: 1764599
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mangafodipir trisodium-enhanced MRI for the detection and characterization of focal hepatic lesions: is delayed imaging useful?
    Chung JJ; Kim MJ; Kim KW
    J Magn Reson Imaging; 2006 May; 23(5):706-11. PubMed ID: 16565954
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mangafodipir trisodium (MnDPDP)-enhanced magnetic resonance imaging of the liver and pancreas.
    Wang C
    Acta Radiol Suppl; 1998; 415():1-31. PubMed ID: 9571956
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatocellular carcinoma: MR imaging with mangafodipir trisodium (Mn-DPDP).
    Murakami T; Baron RL; Peterson MS; Oliver JH; Davis PL; Confer SR; Federle MP
    Radiology; 1996 Jul; 200(1):69-77. PubMed ID: 8657947
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Manganese-DPDP in the MR tomography of malignant liver tumors. The initial results with a new hepatobiliary contrast agent].
    Steudel A; Layer G; Kraheck H; Hartlapp J; Reiser M
    Rofo; 1992 May; 156(5):460-4. PubMed ID: 1596550
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Focal liver lesions: MR imaging with Mn-DPDP--initial clinical results in 40 patients.
    Hamm B; Vogl TJ; Branding G; Schnell B; Taupitz M; Wolf KJ; Lissner J
    Radiology; 1992 Jan; 182(1):167-74. PubMed ID: 1309218
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MRI for detection of hepatocellular carcinoma: comparison of mangafodipir trisodium and gadopentetate dimeglumine contrast agents.
    Youk JH; Lee JM; Kim CS
    AJR Am J Roentgenol; 2004 Oct; 183(4):1049-54. PubMed ID: 15385303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Magnetic resonance with manganese-DPDP (mangafodipir) of focal solid pancreatic lesions.
    Zanello A; Nicoletti R; Brambilla P; Boccuni R; Di Carlo V; Staudacher C; Del Maschio A
    Radiol Med; 2004 Sep; 108(3):194-207. PubMed ID: 15343134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatobiliary-specific MR contrast agents: role in imaging the liver and biliary tree.
    Seale MK; Catalano OA; Saini S; Hahn PF; Sahani DV
    Radiographics; 2009 Oct; 29(6):1725-48. PubMed ID: 19959518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of exocrine cells in pancreatic enhancement using Mn-DPDP-enhanced MR imaging.
    Gong J; Xu J; Zhou K; Shen K
    Chin Med J (Engl); 2002 Sep; 115(9):1363-6. PubMed ID: 12411113
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cirrhosis of the liver: MR imaging with mangafodipir trisodium (Mn-DPDP).
    Murakami T; Baron RL; Federle MP; Peterson MS; Oliver JH; Davis PL; Confer SR
    Radiology; 1996 Feb; 198(2):567-72. PubMed ID: 8596867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. T1 efficacy of EVP-ABD: a potential manganese-based MR contrast agent for hepatic vascular and tissue phase imaging.
    Zuo CS; Seoane P; Lanigan T; Harnish P; Prasad PV; Storey P; Li W; Rofsky NM
    J Magn Reson Imaging; 2002 Dec; 16(6):668-75. PubMed ID: 12451580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adrenal gland enhancement at MR imaging with Mn-DPDP.
    Mitchell DG; Outwater EK; Matteucci T; Rubin DL; Chezmar JL; Saini S
    Radiology; 1995 Mar; 194(3):783-7. PubMed ID: 7862979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mn-DPDP in MR imaging of pancreatic adenocarcinoma: initial clinical experience.
    Gehl HB; Urhahn R; Bohndorf K; Klever P; Hauptmann S; Lodemann KP; Matern S; Schumpelick V; Günther RW
    Radiology; 1993 Mar; 186(3):795-8. PubMed ID: 8430190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [MR imaging of pancreatic lesions with Mn-DPDP. A histopathologic correlation].
    Dobritz M; Fellner FA; Baum U; Nömayr A; Lell M; Klein P; Papadopoulos T; Bautz W
    Rofo; 2002 Jul; 174(7):893-7. PubMed ID: 12101481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of focal liver lesions: use of mangafodipir trisodium (MnDPDP)-enhanced MR images.
    Karabacakoğlu A; Adigüzel Y; Karaköse S; Kayaçetin E; Haykir R
    Turk J Gastroenterol; 2006 Sep; 17(3):164-71. PubMed ID: 16941248
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Manganese DPDP as a contrast medium for MR tomography of focal liver lesions. Tolerance and image quality in 20 patients].
    Kopp AF; Laniado M; Aicher KP; Grönewäller EF; Claussen CD
    Rofo; 1992 Dec; 157(6):539-47. PubMed ID: 1457788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of the hepatobiliary contrast agent mangafodipir trisodium (MN-DPDP) on the imaging properties of abdominal organs.
    Jung G; Heindel W; Krahe T; Kugel H; Walter C; Fischbach R; Klaus H; Lackner K
    Magn Reson Imaging; 1998 Oct; 16(8):925-31. PubMed ID: 9814775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.